A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants with Chronic Rhinosinusitis with Nasal Polyps

Inclusion Criteria:

• Participant has signed, dated and received a copy of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF).

• Participant is aged 18 to 85 years of age (inclusive) at the time of signing theICF.

• Participant has physician diagnosed CRSwNP for at least 6 months prior to Visit 1that fulfills all of the following:

• Severity consistent with need for surgery as defined by an endoscopic bilateralNPS of at least 5 out of 8 and a minimum score of 2 in each nasal cavity atVisit 1 based on central reading, as well as reconfirmed at Visit 2 based onlocal reading.

• Average NCS greater than and equal to (>=) 2 over 14 days before Visit 2.

• Ongoing symptoms of CRSwNP for at least 8 weeks prior to Visit 1 such asrhinorrhea and/or reduction in smell.

• Participant has at least one of the following:

• In the 24 months prior to Visit 1, had a documented exacerbation of nasalpolyposis requiring treatment with systemic corticosteroid.

• A medical contraindication/intolerance to systemic corticosteroid.

• Had prior surgery for NP (cannot be within 6 months prior to Visit 1

• Stable standard of care treatment for CRSwNP for at least 30 days prior to Visit 1.

• At Visit 2, at least 21 days of background mometasone furoate nasal spray (MFNS) (orequivalent) background therapy.

• >=70 percent (%) dosing compliance for MFNS (or equivalent) in the 14 days prior toVisit 2.

• Agrees to follow the required contraceptive techniques/methods

• Female or male participant agrees not to donate eggs or sperm, respectively, for aperiod of 120 days after the last dose of the study drug intervention or at theFinal Visit, whichever occurs last

Exclusion Criteria:

• Has undergone any intranasal and/or sinus surgery (including polypectomy) within 6months prior to Visit 1.

• Expected need, in the opinion of the Investigator, for NP surgery within 12 weeks ofVisit 2.

• Comorbid asthma having forced expiratory volume in 1 second (FEV1) 50% or less ofpredicted normal at Visit 1.

• Conditions making participants non-evaluable at Visit 1 for the primary endpointsuch as sino-nasal or sinus surgery changing the lateral wall structure of the nose,antrochoanal polyps, nasal septal deviation occluding at least one nostril, acutesinusitis, upper respiratory infection, ongoing rhinitis medicamentosa, fungalrhinosinusitis, nasal cavity benign or malignant tumors.

• Concurrent participation in a clinical study or has been treated with aninvestigational drug within 28 days or 5 half-lives, whichever is longer, prior toVisit 1.

• Previous exposure to verekitug (UPB-101) or known allergy/sensitivity to any of itsexcipients.

• Biologic therapy or systemic immunosuppressant to treat inflammatory disease orautoimmune disease within 6 months or 5 half-lives before Visit 1, whichever islonger, with the exception of oral c corticosteroids.

• Any vaccination within the Screening Period and treatment with a live (attenuated)vaccine within 12 weeks before Visit 2.

• Abnormal medical history, physical finding or safety finding and any clinicallaboratory test result outside of the reference ranges that in the opinion of theInvestigator may obscure the study data or interfere with the participant's safety.Participants with any clinically significant cardiac disease and/or ECG abnormality,in the opinion of the Investigator, obtained during the Screening Period should beexcluded from the study.

• Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis withpolyangiitis (Wegener's granulomatosis), Young's syndrome, Kartagener's syndrome orother dyskinetic ciliar syndromes, concomitant cystic fibrosis.

• Participant with comorbid asthma that also has a history or evidence of a clinicallysignificant pulmonary condition (other than asthma).

• History of chronic alcohol or substance use disorder within 12 months prior to Visit